cytidine diphosphate ribitol: serves as the donor of ribitol residues for teichoic acid biosynthesis; minor descriptor (75-83); on-line & Index Medicus search NUCLEOSIDE DIPHOSPHATE SUGARS (75-83) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
CDP-ribitol : A nucleotide-alditol having cytosine as the nucleobase and ribitol as the alditol portion. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 165130 |
| CHEBI ID | 16022 |
| SCHEMBL ID | 22098796 |
| MeSH ID | M0262518 |
| Synonym |
|---|
| cytidine diphosphate ribitol |
| CHEBI:16022 |
| cytidine 5'-(trihydrogen diphosphate), p'-5-ester with d-ribitol |
| cytidine 5'-{3-[(2r,3s,4s)-2,3,4,5-tetrahydroxypentyl] dihydrogen diphosphate} |
| cdp ribitol |
| cdpribitol |
| C00789 |
| 3506-17-0 |
| cdp 5-ester with d-ribitol |
| cdp-ribitol |
| cdp-l-ribitol |
| [[(2r,3s,4r,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3s,4s)-2,3,4,5-tetrahydroxypentyl] hydrogen phosphate |
| cytidine 5'-{3-[(2r,3r,4s)-2,3,4,5-tetrahydroxypentyl] dihydrogen diphosphate} |
| DTXSID70188561 |
| v2v , |
| Q27098341 |
| [(2r,3s,4r,5r)-5-(4-amino-2-oxopyrimidin-1(2h)-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl (2r,3s,4s)-2,3,4,5-tetrahydroxypentyl dihydrogen diphosphate (non-preferred name) |
| SCHEMBL22098796 |
| Class | Description |
|---|---|
| nucleotide-alditol | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.34) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (9.09%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (90.91%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||